Medical News

---

• N-terminal of ADAMTS13 essential for arterial thrombosis inhibition
• Young people should increase dairy intake to improve CVD risk factors
• Adiposity explains associations between sedentary behavior and CV risk factors
• Variants in <i>PPARγ</i> may increase risk for gestational diabetes
• Survival after first MI remains poor among diabetics
• Survival rates improved in centers combining high-quality AMI, HF care
• Bleeding risk terminates apixaban trial

N-terminal of ADAMTS13 essential for arterial thrombosis inhibition Posted: 28 Jul 2011 05:00 PM PDT The amino terminus of the metalloprotease ADAMTS13 has a crucial role in the modulation of arterial thromboses, study findings indicate.

Young people should increase dairy intake to improve CVD risk factors Posted: 28 Jul 2011 05:00 PM PDT Researchers say that dairy fatty acid intake early in life should be increased, after finding that dairy-specific saturated fats were beneficially associated with a reduction in cardiovascular disease risk factors among adolescents, especially those who were overweight.

Adiposity explains associations between sedentary behavior and CV risk factors Posted: 28 Jul 2011 05:00 PM PDT Markers of adiposity largely explain the association between sedentary behavior and cardiometabolic risk factors, study findings suggest.

Variants in <i>PPARγ</i> may increase risk for gestational diabetes Posted: 28 Jul 2011 05:00 PM PDT Two variants in the peroxisome proliferator-activated receptor-γ gene are associated with increased risk for gestational diabetes mellitus, report French researchers.

Survival after first MI remains poor among diabetics Posted: 28 Jul 2011 05:00 PM PDT Long-term survival after a first myocardial infarction is significantly lower among patients with diabetes than those without the condition, researchers report.

Survival rates improved in centers combining high-quality AMI, HF care Posted: 28 Jul 2011 05:00 PM PDT Hospitals that provide superior care for both acute myocardial infarction and heart failure patients have better survival rates than those that provide superior care for only one of these conditions, say researchers.

Bleeding risk terminates apixaban trial Posted: 28 Jul 2011 05:00 PM PDT Addition of apixaban to antiplatelet therapy for acute coronary syndrome patients increases major bleeding without significantly reducing recurrent ischemic events, results from the prematurely terminated APPRAISE-2 trial show.

You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 20 West Kinzie, Chicago IL USA 60610